50
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Predicting progression to Alzheimer’s disease with human hippocampal progenitors exposed to serum

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Adult hippocampal neurogenesis is important for learning and memory and is altered early in Alzheimer’s disease. As hippocampal neurogenesis is modulated by the circulatory systemic environment, evaluating a proxy of how hippocampal neurogenesis is affected by the systemic milieu could serve as an early biomarker for Alzheimer’s disease progression. Here, we used an in vitro assay to model the impact of systemic environment on hippocampal neurogenesis. A human hippocampal progenitor cell line was treated with longitudinal serum samples from individuals with mild cognitive impairment, who either progressed to Alzheimer’s disease or remained cognitively stable. Mild cognitive impairment to Alzheimer’s disease progression was characterized most prominently with decreased proliferation, increased cell death and increased neurogenesis. A subset of ‘baseline’ cellular readouts together with education level were able to predict Alzheimer’s disease progression. The assay could provide a powerful platform for early prognosis, monitoring disease progression and further mechanistic studies.

          Abstract

          Adult hippocampal neurogenesis is altered early in the course of Alzheimer’s disease. Maruszak et al. show that serum from patients with MCI who do versus do not progress to Alzheimer’s disease differentially affects the fate of hippocampal stem cells in vitro, suggesting that this assay could help predict disease progression.

          Related collections

          Most cited references71

          • Record: found
          • Abstract: found
          • Article: not found

          Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group* under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

          Neurology, 34(7), 939-939
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Mild cognitive impairment: clinical characterization and outcome.

            Subjects with a mild cognitive impairment (MCI) have a memory impairment beyond that expected for age and education yet are not demented. These subjects are becoming the focus of many prediction studies and early intervention trials. To characterize clinically subjects with MCI cross-sectionally and longitudinally. A prospective, longitudinal inception cohort. General community clinic. A sample of 76 consecutively evaluated subjects with MCI were compared with 234 healthy control subjects and 106 patients with mild Alzheimer disease (AD), all from a community setting as part of the Mayo Clinic Alzheimer's Disease Center/Alzheimer's Disease Patient Registry, Rochester, Minn. The 3 groups of individuals were compared on demographic factors and measures of cognitive function including the Mini-Mental State Examination, Wechsler Adult Intelligence Scale-Revised, Wechsler Memory Scale-Revised, Dementia Rating Scale, Free and Cued Selective Reminding Test, and Auditory Verbal Learning Test. Clinical classifications of dementia and AD were determined according to the Diagnostic and Statistical Manual of Mental Disorders, Revised Third Edition and the National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders Association criteria, respectively. The primary distinction between control subjects and subjects with MCI was in the area of memory, while other cognitive functions were comparable. However, when the subjects with MCI were compared with the patients with very mild AD, memory performance was similar, but patients with AD were more impaired in other cognitive domains as well. Longitudinal performance demonstrated that the subjects with MCI declined at a rate greater than that of the controls but less rapidly than the patients with mild AD. Patients who meet the criteria for MCI can be differentiated from healthy control subjects and those with very mild AD. They appear to constitute a clinical entity that can be characterized for treatment interventions.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Adult hippocampal neurogenesis is abundant in neurologically healthy subjects and drops sharply in patients with Alzheimer’s disease

              The hippocampus is one of the most affected areas in Alzheimer's disease (AD)1. Moreover, this structure hosts one of the most unique phenomena of the adult mammalian brain, namely, the addition of new neurons throughout life2. This process, called adult hippocampal neurogenesis (AHN), confers an unparalleled degree of plasticity to the entire hippocampal circuitry3,4. Nonetheless, direct evidence of AHN in humans has remained elusive. Thus, determining whether new neurons are continuously incorporated into the human dentate gyrus (DG) during physiological and pathological aging is a crucial question with outstanding therapeutic potential. By combining human brain samples obtained under tightly controlled conditions and state-of-the-art tissue processing methods, we identified thousands of immature neurons in the DG of neurologically healthy human subjects up to the ninth decade of life. These neurons exhibited variable degrees of maturation along differentiation stages of AHN. In sharp contrast, the number and maturation of these neurons progressively declined as AD advanced. These results demonstrate the persistence of AHN during both physiological and pathological aging in humans and provide evidence for impaired neurogenesis as a potentially relevant mechanism underlying memory deficits in AD that might be amenable to novel therapeutic strategies.
                Bookmark

                Author and article information

                Contributors
                Journal
                Brain
                Brain
                brainj
                Brain
                Oxford University Press (US )
                0006-8950
                1460-2156
                May 2023
                27 January 2023
                27 January 2023
                : 146
                : 5
                : 2045-2058
                Affiliations
                Department of Basic and Clinical Neuroscience, Institute of Psychiatry Psychology & Neuroscience, King’s College London , London, SE5 9RX, UK
                Department of Basic and Clinical Neuroscience, Institute of Psychiatry Psychology & Neuroscience, King’s College London , London, SE5 9RX, UK
                Department of Basic and Clinical Neuroscience, Institute of Psychiatry Psychology & Neuroscience, King’s College London , London, SE5 9RX, UK
                Department of Basic and Clinical Neuroscience, Institute of Psychiatry Psychology & Neuroscience, King’s College London , London, SE5 9RX, UK
                Department of Psychiatry, University of Oxford , Oxford, OX3 7JX, UK
                Department of Psychiatry, University of Oxford , Oxford, OX3 7JX, UK
                Department of Basic and Clinical Neuroscience, Institute of Psychiatry Psychology & Neuroscience, King’s College London , London, SE5 9RX, UK
                Department of Population Health Sciences, King's College London , London, SE1 1UL, UK
                Netherlands Institute for Neuroscience , 1105 BA Amsterdam, The Netherlands
                Neurochemistry Lab and Biobank, Department of Clinical Chemistry, Amsterdam Neuroscience, VU University Medical Center , 1007 MB Amsterdam, The Netherlands
                Department of Psychiatry, University of Oxford , Oxford, OX3 7JX, UK
                Neurochemistry Lab and Biobank, Department of Clinical Chemistry, Amsterdam Neuroscience, VU University Medical Center , 1007 MB Amsterdam, The Netherlands
                Department of Psychiatry and Neuropsychology, Alzheimer Center Limburg, School for Mental Health and Neuroscience, Maastricht University , 6200 MD Maastricht, The Netherlands
                Department of Neurology, Alzheimer Center, VU University Medical Center , 1081 HZ Amsterdam, The Netherlands
                Department of Basic and Clinical Neuroscience, Institute of Psychiatry Psychology & Neuroscience, King’s College London , London, SE5 9RX, UK
                Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital , S-431 80 Mölndal, Sweden
                Department of Neurodegenerative Disease, UCL Institute of Neurology , London, WC1N 3BG, UK
                Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy at the University of Gothenburg , S-431 80 Mölndal, Sweden
                UK Dementia Research Institute at UCL , London, WC1E 6BT, UK
                Department of Psychiatry, University of Oxford , Oxford, OX3 7JX, UK
                Janssen Medical UK , B-2340 Beerse, Belgium
                Department of Basic and Clinical Neuroscience, Institute of Psychiatry Psychology & Neuroscience, King’s College London , London, SE5 9RX, UK
                Author notes
                Correspondence to: Sandrine Thuret Maurice Wohl Clinical Neuroscience Institute, Department of Basic and Clinical Neuroscience Institute of Psychiatry, Psychology & Neuroscience King’s College London, London, UK E-mail: sandrine.1.thuret@ 123456kcl.ac.uk

                Aleksandra Maruszak, Edina Silajdžić and Hyunah Lee contributed equally to this work.

                Author information
                https://orcid.org/0000-0003-3930-4354
                https://orcid.org/0000-0003-1260-8083
                Article
                awac472
                10.1093/brain/awac472
                10151193
                36703180
                f15631a3-e50c-41d9-a627-a1c570775e4a
                © The Author(s) 2023. Published by Oxford University Press on behalf of the Guarantors of Brain.

                This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

                History
                : 02 August 2022
                : 11 October 2022
                : 10 November 2022
                : 24 January 2023
                Page count
                Pages: 14
                Funding
                Funded by: John and Lucille van Geest Foundation (AM);
                Funded by: the Medical Research Council UK;
                Award ID: MR/K500811/1
                Funded by: Cohen Charitable Trust (TM);
                Funded by: the Medical Research Councils UK;
                Award ID: MR/N030087/1
                Award ID: MR/S00484X/1
                Award ID: MC_PC_18052
                Funded by: the Galen and Hilary Weston Foundation;
                Funded by: Rhodes Trust;
                Categories
                Original Article
                AcademicSubjects/MED00310
                AcademicSubjects/SCI01870

                Neurosciences
                alzheimer’s disease,prognostic biomarker,neurogenesis,hippocampal progenitors
                Neurosciences
                alzheimer’s disease, prognostic biomarker, neurogenesis, hippocampal progenitors

                Comments

                Comment on this article